United Therapeutics Co. (NASDAQ:UTHR) Receives $388.25 Average Target Price from Analysts

United Therapeutics Co. (NASDAQ:UTHR) has been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $388.25.

A number of brokerages recently commented on UTHR. HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $919,164.36. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,255 shares of company stock worth $32,614,521 in the last three months. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. grew its position in United Therapeutics by 21.9% in the third quarter. Victory Capital Management Inc. now owns 186,819 shares of the biotechnology company’s stock valued at $66,947,000 after acquiring an additional 33,599 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in United Therapeutics by 20.9% in the third quarter. Oppenheimer & Co. Inc. now owns 6,248 shares of the biotechnology company’s stock valued at $2,239,000 after acquiring an additional 1,078 shares in the last quarter. Archer Investment Corp acquired a new stake in United Therapeutics in the third quarter valued at approximately $283,000. Nicollet Investment Management Inc. grew its position in United Therapeutics by 1.1% in the third quarter. Nicollet Investment Management Inc. now owns 5,833 shares of the biotechnology company’s stock valued at $2,090,000 after acquiring an additional 61 shares in the last quarter. Finally, Seizert Capital Partners LLC grew its position in United Therapeutics by 59.2% in the third quarter. Seizert Capital Partners LLC now owns 38,906 shares of the biotechnology company’s stock valued at $13,942,000 after acquiring an additional 14,465 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.5 %

Shares of NASDAQ UTHR opened at $318.85 on Friday. The stock has a market cap of $14.32 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics has a 52 week low of $221.53 and a 52 week high of $417.82. The company’s 50-day moving average price is $347.20 and its 200 day moving average price is $357.65.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company earned $4.36 EPS. As a group, research analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.